MedTrace Logo

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes

NCT02312063 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-07-01

Study results available
· View outcomes & findings →

Summary

In a prospective, randomized case-controlled study, the investigators hope to demonstrate a positive correlation of plasma levels of EPA and DHA as well as fish intake with the HbA1c-lowering effect of sitagliptin but not with the active comparator glimepiride.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sitagliptin

DRUG

Glimepiride

Sponsors & Collaborators

  • Saiseikai Noe Hospital Osaka

    collaborator UNKNOWN

  • Kansai Electric Power Hospital

    lead OTHER

Principal Investigators

  • Yutaka Seino, MD, PhD · Kansai Electric Power Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312063 on ClinicalTrials.gov